[go: up one dir, main page]

PE20150218A1 - Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen - Google Patents

Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Info

Publication number
PE20150218A1
PE20150218A1 PE2014001093A PE2014001093A PE20150218A1 PE 20150218 A1 PE20150218 A1 PE 20150218A1 PE 2014001093 A PE2014001093 A PE 2014001093A PE 2014001093 A PE2014001093 A PE 2014001093A PE 20150218 A1 PE20150218 A1 PE 20150218A1
Authority
PE
Peru
Prior art keywords
carbonyl
contain
pharmaceutical compositions
alkyl
preparation procedure
Prior art date
Application number
PE2014001093A
Other languages
English (en)
Inventor
Tiran Arnaud Le
Diguarher Thierry Le
Jer& ;Me-Beno& ;T Starck
Jean-Michel Henlin
Anne-Fran& ;Oise Guillouzic
Nanteuil Guillaume De
Olivier Geneste
James Edward Paul Davidson
James Brooke Murray
I-Jen Chen
Original Assignee
Servier Lab
Vernalis Randd Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150218(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab, Vernalis Randd Ltd filed Critical Servier Lab
Publication of PE20150218A1 publication Critical patent/PE20150218A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1098Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A DERIVADOS DE FOSFATOS DE FORMULA (I) DONDE X E Y SON CADA UNO C O N; A1 Y A2 FORMAN JUNTO CON LOS ATOMOS A LOS QUE ESTAN UNIDOS UN HETEROCICLO DE 5 A 7 ESLABONES O A1 Y A2 SON CADA UNO H, ALQUILO(C1-C6), ENTRE OTROS; T ES H, ALQUILO(C1-C6), ENTRE OTROS; R3 ES ALQUILO(C1-C6), CICLOALQUILO, ARILO, ENTRE OTROS; R4 ES ARILO, HETEROARILO, ENTRE OTROS; R5 ES H, HALOGENO, ENTRE OTROS; Ra, Rb, Rc Y Rd SON CADA UNO HALOGENO, ALCOXI(C1-C6), HIDROXI, TRIFLUOROMETOXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-[{[3-(6-{[(3S)-3-(MORFOLIN-4-ILMETIL)-3,4-DIHIDROISOQUINOLIN-2(1H)-IL]CARBONIL}-1,3-BENZODIOXOL-5-IL)-5,6,7,8-TETRAHIDROINDOLIZIN-1-IL]CARBONIL}(FENIL)AMINO]FENIL FOSFATO DE DISODIO; 4-[{[5-(5-CLORO-2-{[(3S)-3-(MORFOLIN-4-ILMETIL)-3,4-DIHIDROISOQUINOLIN-2(1H)-IL]CARBONIL}FENIL)-1,2-DIMETIL-1H-PIRROL-3-IL]CARBONIL}(PIRIDIN-4-IL)AMINO]FENIL FOSFATO DE DISODIO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE CANCER, ENFERMEDADES AUTOINMUNES
PE2014001093A 2013-07-23 2014-07-10 Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen PE20150218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357259A FR3008979B1 (fr) 2013-07-23 2013-07-23 Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PE20150218A1 true PE20150218A1 (es) 2015-02-14

Family

ID=50288170

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001093A PE20150218A1 (es) 2013-07-23 2014-07-10 Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Country Status (48)

Country Link
US (3) US9115159B2 (es)
EP (1) EP2829545B1 (es)
JP (1) JP5894638B2 (es)
KR (2) KR101713103B1 (es)
CN (1) CN104341451B (es)
AP (1) AP2014007773A0 (es)
AR (1) AR097008A1 (es)
AU (1) AU2014203808B2 (es)
BR (1) BR102014017997B1 (es)
CA (1) CA2856886C (es)
CL (1) CL2014001865A1 (es)
CR (1) CR20140336A (es)
CU (1) CU24316B1 (es)
CY (1) CY1117834T1 (es)
DK (1) DK2829545T3 (es)
DO (1) DOP2014000163A (es)
EA (1) EA027444B1 (es)
EC (1) ECSP14008757A (es)
ES (1) ES2593417T3 (es)
FR (1) FR3008979B1 (es)
GE (1) GEP201706704B (es)
HK (1) HK1204623A1 (es)
HR (1) HRP20161202T8 (es)
HU (1) HUE029616T2 (es)
IL (1) IL233580B (es)
JO (1) JO3160B1 (es)
MA (1) MA37213B1 (es)
MD (1) MD4551C1 (es)
ME (1) ME02641B (es)
MX (1) MX351467B (es)
MY (1) MY173258A (es)
NI (1) NI201400080A (es)
PE (1) PE20150218A1 (es)
PH (1) PH12014000194A1 (es)
PL (1) PL2829545T3 (es)
PT (1) PT2829545T (es)
RS (1) RS55098B1 (es)
RU (1) RU2617682C2 (es)
SA (1) SA114350669B1 (es)
SG (1) SG10201403939WA (es)
SI (1) SI2829545T1 (es)
SV (1) SV2014004771A (es)
TN (1) TN2014000301A1 (es)
TW (1) TWI527824B (es)
UA (1) UA119738C2 (es)
UY (1) UY35661A (es)
WO (1) WO2015011399A1 (es)
ZA (1) ZA201405418B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008977A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UY37316A (es) * 2016-07-07 2018-01-31 Servier Lab Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
UA125138C2 (uk) * 2016-07-22 2022-01-19 Ле Лаборатуар Сервьє Комбінація інгібітора bcl-2 та інгібітора mcl-1, їхнє застосування і фармацевтичні композиції
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
EA039621B1 (ru) * 2017-06-09 2022-02-17 Ле Лаборатуар Сервье Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
TWI672302B (zh) * 2017-07-06 2019-09-21 法商施維雅藥廠 Bcl-2抑制劑之新結晶型、其製備方法及含其之醫藥組合物
FR3072679B1 (fr) * 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP7523351B2 (ja) 2018-01-31 2024-07-26 デシフェラ・ファーマシューティカルズ,エルエルシー 肥満細胞症の治療のための併用療法
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ,エルエルシー 消化管間質腫瘍の治療のための併用療法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CN110606860B (zh) * 2019-09-29 2021-12-10 上海勋和医药科技有限公司 一种吡啶磺酰胺磷酸酯类化合物、其制备方法及其用途
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
NZ789199A (en) 2019-12-30 2025-07-25 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
EP4304588A4 (en) * 2021-03-12 2025-01-29 Eil Therapeutics, Inc. COMPOUNDS CONTAINING TETRAHYDROINDOLIZIN-1-CARBOXAMIDE AS BCL-2 INHIBITORS
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4901102B2 (ja) * 2002-05-03 2012-03-21 エクセリクシス, インク. プロテインキナーゼモジュレーターおよびその使用方法
AU2003249713A1 (en) * 2002-07-03 2004-01-23 Axys Pharmaceuticals, Inc. 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
GB0224557D0 (en) * 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
AU2006331765A1 (en) * 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
US7902218B2 (en) 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
JP5496877B2 (ja) * 2007-04-16 2014-05-21 アッヴィ・インコーポレイテッド 7−置換インドールMcl−1阻害薬
EP2149560B1 (en) 2007-05-22 2015-05-13 Astellas Pharma Inc. 1-substituted tetrahydroisoquinoline compound
US20090221612A1 (en) * 2008-02-13 2009-09-03 Mitchell Scott A Certain substituted amides, method of making, and method of use thereof
WO2010080503A1 (en) * 2008-12-19 2010-07-15 Genentech, Inc. Heterocyclic compounds and methods of use
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
US20120301080A1 (en) 2011-05-23 2012-11-29 Senko Advanced Components, Inc. True one piece housing fiber optic adapter
AU2012355619A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355624A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EA201491264A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
CN103177906A (zh) 2011-12-26 2013-06-26 西门子公司 用于中压开关设备的断路器
ITPR20110103A1 (it) 2011-12-27 2013-06-28 G E A F S R L Metodo e apparato per la sterilizzazione di una soluzione liquida mediante radio frequenza
US9114953B2 (en) 2011-12-29 2015-08-25 Inventio Ag Emergency operation of elevators based on an indicated emergency condition
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE212013000059U1 (de) 2012-01-24 2014-09-11 Danfoss Power Electronics A/S Entfeuchter

Also Published As

Publication number Publication date
HUE029616T2 (en) 2017-03-28
EA201400754A2 (ru) 2014-12-30
ME02641B (me) 2017-06-20
PH12014000194B1 (en) 2015-06-29
US9597341B2 (en) 2017-03-21
GEP201706704B (en) 2017-07-25
WO2015011399A1 (fr) 2015-01-29
RS55098B1 (sr) 2016-12-30
FR3008979A1 (fr) 2015-01-30
EP2829545B1 (fr) 2016-06-22
MA37213A1 (fr) 2016-06-30
CN104341451A (zh) 2015-02-11
HRP20161202T8 (hr) 2016-12-30
AU2014203808B2 (en) 2018-09-20
CA2856886A1 (fr) 2015-01-23
TN2014000301A1 (fr) 2015-12-21
RU2617682C2 (ru) 2017-04-26
CR20140336A (es) 2015-10-07
MY173258A (en) 2020-01-09
US20150313923A1 (en) 2015-11-05
US20170143746A1 (en) 2017-05-25
IL233580B (en) 2020-03-31
BR102014017997B1 (pt) 2020-05-19
JP2015028017A (ja) 2015-02-12
HK1201536A1 (zh) 2015-09-04
HRP20161202T1 (hr) 2016-11-04
JP5894638B2 (ja) 2016-03-30
TWI527824B (zh) 2016-04-01
SI2829545T1 (sl) 2016-10-28
MA37213B1 (fr) 2017-03-31
BR102014017997A2 (pt) 2015-11-17
UA119738C2 (uk) 2019-08-12
FR3008979B1 (fr) 2015-07-24
AP2014007773A0 (en) 2014-07-31
KR20170001694A (ko) 2017-01-04
SV2014004771A (es) 2015-01-28
CL2014001865A1 (es) 2015-06-26
MD4551B1 (ro) 2018-02-28
MX2014008866A (es) 2015-07-21
MX351467B (es) 2017-10-17
NZ627178A (en) 2016-01-29
ZA201405418B (en) 2020-02-26
EP2829545A1 (fr) 2015-01-28
IL233580A0 (en) 2014-11-02
TW201504254A (zh) 2015-02-01
UY35661A (es) 2015-02-27
DOP2014000163A (es) 2015-01-15
CY1117834T1 (el) 2017-05-17
DK2829545T3 (en) 2016-09-19
KR20150011785A (ko) 2015-02-02
MD4551C1 (ro) 2018-09-30
NI201400080A (es) 2014-10-24
AU2014203808A1 (en) 2015-02-12
CU24316B1 (es) 2018-02-08
RU2014130129A (ru) 2016-02-10
HK1204623A1 (en) 2015-11-27
EA201400754A3 (ru) 2015-03-31
SG10201403939WA (en) 2015-02-27
PH12014000194A1 (en) 2015-06-29
KR101713103B1 (ko) 2017-03-07
PT2829545T (pt) 2016-07-13
CA2856886C (fr) 2016-08-02
CN104341451B (zh) 2018-04-03
ES2593417T3 (es) 2016-12-09
ECSP14008757A (es) 2016-01-29
AR097008A1 (es) 2016-02-10
US20150031648A1 (en) 2015-01-29
CU20140095A7 (es) 2016-02-29
SA114350669B1 (ar) 2016-04-11
US9115159B2 (en) 2015-08-25
PL2829545T3 (pl) 2016-12-30
EA027444B1 (ru) 2017-07-31
JO3160B1 (ar) 2017-09-20
MD20140073A2 (en) 2015-01-31

Similar Documents

Publication Publication Date Title
PE20150218A1 (es) Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20150399A1 (es) Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20160240A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20211411A1 (es) Compuestos de anillo fusionado
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
PE20171240A1 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
PE20160875A1 (es) Compuestos de biaril-amida como inhibidores de cinasa
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR112216A1 (es) Derivados de azaquinolina
PE20201448A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
PE20121815A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20142376A1 (es) Fluormetil-5,6-dihidro-4h-[1,3]oxazinas
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
AR103252A1 (es) Compuestos de quinazolina
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
AR064454A1 (es) Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
EA201490491A1 (ru) Производные 2-амино-4-(пиридин-2-ил)-5,6-дигидро-4h-1,3-оксазинов и их использование в качестве ингибиторов bace-1 и/или bace-2
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa

Legal Events

Date Code Title Description
FG Grant, registration